Cingulate (CING) Retained Earnings (2021 - 2026)
Cingulate's (CING) quarterly Retained Earnings came in at -$132.4 million in Q4 2025, down 20.45% YoY from -$166.4 million in Q4 2024, and down 202.18% on a QoQ basis from $129.6 million in Q3 2025.
Cingulate (CING) Retained Earnings (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Retained Earnings data on file, last reported at -$132.4 million in Q4 2025.
- Quarterly Retained Earnings fell 20.45% year-over-year to -$132.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.4 million (down 20.45% YoY) and the FY2025 annual result came in at -$132.4 million, down 20.45% from the prior year.
- Retained Earnings fell to -$132.4 million in Q4 2025, from $129.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $129.6 million in Q3 2025 to a low of -$132.4 million in Q4 2025.
- A 5-year average of -$11.0 million and a median of -$25.9 million in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 2275568.3% in 2023, down 2637822.49% in 2023.
- Tracing CING's Retained Earnings over 5 years: stood at -$51.7 million in 2021, then jumped by 241.67% to $73.3 million in 2022, then increased by 17.44% to $86.1 million in 2023, then tumbled by 227.71% to -$109.9 million in 2024, then dropped by 20.45% to -$132.4 million in 2025.
- The last three Retained Earnings figures came in at -$132.4 million (Q4 2025), $129.6 million (Q3 2025), and -$112.3 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 171.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 171.02 Mn |
| Dec 31, 2025 | -132.40 Mn |
| Sep 30, 2025 | 129.58 Mn |
| Mar 31, 2025 | -112.30 Mn |
| Dec 31, 2024 | -109.93 Mn |
| Sep 30, 2024 | 114.39 Mn |
| Jun 30, 2024 | -99.13 Mn |
| Mar 31, 2024 | -95.92 Mn |
| Dec 31, 2023 | 86.07 Mn |
| Sep 30, 2023 | 85.91 Mn |
| Jun 30, 2023 | 73.93 Mn |
| Mar 31, 2023 | -73.41 Mn |
| Dec 31, 2022 | 73.29 Mn |
| Sep 30, 2022 | -64.80 Mn |
| Jun 30, 2022 | -3,249.00 |
| Mar 31, 2022 | -2,783.00 |
| Dec 31, 2021 | -51.73 Mn |